CorePharma (2)

CorePharma is a well-established, private contract development and manufacturing organization (CDMO) and generic drug developer with over two decades of operation. The company's business model is centered on providing end-to-end pharmaceutical services—including R&D, analytical testing, manufacturing, and packaging—while also developing its own generic and branded product portfolio. With significant manufacturing capacity exceeding 2 billion units annually and a strong emphasis on quality and regulatory compliance, CorePharma serves as a partner for other pharmaceutical companies while maintaining its own product pipeline. Its privately-held status and family-oriented corporate culture underpin its long-term, value-driven approach in the competitive generic pharmaceuticals market.

Integrated development, testing, manufacturing, and packaging platform for oral solid dosage forms (IR & ER tablets/capsules), with capabilities for complex processes and commercial-scale production exceeding 2 billion units/year.

CorePharma competes with large global generic manufacturers (e.g., Teva, Mylan) and a fragmented field of CDMOs specializing in oral dosages. Its competitive differentiation lies in its integrated service model, focus on complex processes, controlled substance capabilities, and a quality-centric, privately-held culture emphasizing long-term partnerships.